IL316349A - Treatment methods for focal segmental glomerulosclerosis with atrasentan - Google Patents
Treatment methods for focal segmental glomerulosclerosis with atrasentanInfo
- Publication number
- IL316349A IL316349A IL316349A IL31634924A IL316349A IL 316349 A IL316349 A IL 316349A IL 316349 A IL316349 A IL 316349A IL 31634924 A IL31634924 A IL 31634924A IL 316349 A IL316349 A IL 316349A
- Authority
- IL
- Israel
- Prior art keywords
- atrasentan
- methods
- focal segmental
- segmental glomerulosclerosis
- treating focal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343574P | 2022-05-19 | 2022-05-19 | |
| PCT/US2023/022681 WO2023225163A1 (en) | 2022-05-19 | 2023-05-18 | Methods of treating focal segmental glomerulosclerosis with atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316349A true IL316349A (en) | 2024-12-01 |
Family
ID=88836135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316349A IL316349A (en) | 2022-05-19 | 2023-05-18 | Treatment methods for focal segmental glomerulosclerosis with atrasentan |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250352511A1 (enExample) |
| EP (1) | EP4525857A4 (enExample) |
| JP (1) | JP2025517355A (enExample) |
| KR (1) | KR20250013180A (enExample) |
| CN (1) | CN119325377A (enExample) |
| AU (1) | AU2023271840A1 (enExample) |
| CA (1) | CA3252232A1 (enExample) |
| IL (1) | IL316349A (enExample) |
| MX (1) | MX2024013985A (enExample) |
| WO (1) | WO2023225163A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| US20170014386A1 (en) * | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| CA3010593C (en) * | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| IL294410B2 (en) * | 2016-11-23 | 2024-02-01 | Chemocentryx Inc | A method for the treatment of focal segmental tuberous sclerosis |
| HRP20260121T1 (hr) * | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
-
2023
- 2023-05-18 JP JP2024568249A patent/JP2025517355A/ja active Pending
- 2023-05-18 IL IL316349A patent/IL316349A/en unknown
- 2023-05-18 KR KR1020247041241A patent/KR20250013180A/ko active Pending
- 2023-05-18 AU AU2023271840A patent/AU2023271840A1/en active Pending
- 2023-05-18 CN CN202380039968.2A patent/CN119325377A/zh active Pending
- 2023-05-18 CA CA3252232A patent/CA3252232A1/en active Pending
- 2023-05-18 WO PCT/US2023/022681 patent/WO2023225163A1/en not_active Ceased
- 2023-05-18 EP EP23808292.9A patent/EP4525857A4/en active Pending
- 2023-05-18 US US18/867,358 patent/US20250352511A1/en active Pending
-
2024
- 2024-11-12 MX MX2024013985A patent/MX2024013985A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025517355A (ja) | 2025-06-05 |
| EP4525857A1 (en) | 2025-03-26 |
| AU2023271840A1 (en) | 2024-10-31 |
| EP4525857A4 (en) | 2026-05-20 |
| KR20250013180A (ko) | 2025-01-31 |
| MX2024013985A (es) | 2025-02-10 |
| US20250352511A1 (en) | 2025-11-20 |
| CA3252232A1 (en) | 2023-11-23 |
| CN119325377A (zh) | 2025-01-17 |
| WO2023225163A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266751A (en) | A method for the treatment of focal segmental tuberous sclerosis | |
| ZA202002049B (en) | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists | |
| PT3380041T (pt) | Lente intraocular com uma profundidade de foco estendida | |
| EP3780834A4 (en) | METHOD FOR TRANSMITTING PLANNING REQUESTS AND DEVICE FOR TRANSMITTING PLANNING REQUESTS | |
| IL291687A (en) | Methods for treating myelofibrosis and related conditions | |
| EP3843398A4 (en) | VIDEO DECODING METHOD AND VIDEO DECODER | |
| IL257868A (en) | Method and system for focus adjustment a multi-beam scanning electron microscopy system | |
| DK3795181T3 (da) | Behandling af amd ved anvendelse af aav2-variant med aflibercept | |
| EP4076652A4 (en) | METHOD FOR TREATING IGA NEPHROPATHY WITH ARASENTAN | |
| EA201892485A1 (ru) | Способ получения соединения диарилтиогидантоина | |
| DK3728410T3 (da) | Fremgangsmåde til behandling af lignocelluloseholdig biomasse | |
| SG11202108029XA (en) | Methods of treating multiple myeloma | |
| GB2604030B (en) | Improved survivability of wave energy convertors | |
| EP3900329A4 (en) | OPTIMIZED COMBINATION OF VIDEO CHUNKS | |
| EP4037680A4 (en) | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSSCLEROSIS AND DIABETIC KIDNEY DISEASE | |
| IL277198A (en) | Optimizing BPH treatment using HOLEP (prostate enucleation by holmium laser) | |
| IL277981A (en) | Cancer treatment methods | |
| ZA202201319B (en) | Safe, environmentally friendly and controllable process for synthesizing diepoxide | |
| IL278759A (en) | A method for treating clinical depression | |
| IL286297A (en) | Minimal residual cancer treatment methods | |
| HUE057197T2 (hu) | Eljárás nafta hirdogénezõ kezelésére | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| DK3899113T3 (da) | Fremgangsmåde til behandling af lyocellfibre | |
| GB201918123D0 (en) | High efficiency water treatment process | |
| GB201804952D0 (en) | Improved scanning optical microscope |